Patents by Inventor Gabriele Matschiner
Gabriele Matschiner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170340703Abstract: The present invention relates to novel muteins derived from human tear lipocalin, which bind to IL 4 receptor alpha. The sequences of the muteins comprise particular combinations of amino acids. In particular a mutated amino acid residue is present at any one or more of the sequence positions 27, 28 30, 31, 33, 53, 57, 61, 64, 66, 80, 83, 104-106 and 108 of the linear polypeptide sequence of the mature human tear lipocalin. A mutated amino acid residue is also present at any 2 or more of the sequence positions 26, 32, 34, 55, 56, 58 and 63 of the linear polypeptide sequence of the mature human tear lipocalin. The invention also provides a corresponding nucleic acid molecule encoding such a mutein and a method for producing such a mutein and its encoding nucleic acid molecule.Type: ApplicationFiled: June 5, 2017Publication date: November 30, 2017Applicant: Pieris Pharmaceuticals GmbHInventors: Andreas HOHLBAUM, Alexandra BAEHRE, Gabriele MATSCHINER, Stefan TRENTMANN, Klaus KIRCHFELD, Hans-Juergen CHRISTIAN
-
Patent number: 9751920Abstract: The present invention relates to novel muteins derived from human tear lipocalin having affinity to human c-Met receptor tyrosin kinase (c-Met). The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.Type: GrantFiled: December 14, 2015Date of Patent: September 5, 2017Assignee: PIERIS PHARMACEUTICALS GMBHInventors: Gabriele Matschiner, Andreas Hohlbaum, Martin Huelsmeyer, Stefan Trentmann
-
Patent number: 9687524Abstract: The present invention relates to novel muteins derived from human tear lipocalin, which bind to IL 4 receptor alpha. The sequences of the muteins comprise particular combinations of amino acids. In particular a mutated amino acid residue is present at any one or more of the sequence positions 27, 28, 30, 31, 33, 53, 57, 61, 64, 66, 80, 83, 104-106 and 108 of the linear polypeptide sequence of the mature human tear lipocalin. A mutated amino acid residue is also present at any 2 or more of the sequence positions 26, 32, 34, 55, 56, 58 and 63 of the linear polypeptide sequence of the mature human tear lipocalin. The invention also provides a corresponding nucleic acid molecule encoding such a mutein and a method for producing such a mutein and its encoding nucleic acid molecule.Type: GrantFiled: March 23, 2015Date of Patent: June 27, 2017Assignee: Pieris Pharmaceuticals GmbHInventors: Andreas Hohlbaum, Alexandra Baehre, Gabriele Matschiner, Stefan Trentmann, Klaus Kirchfeld, Hans-Juergen Christian
-
Publication number: 20170173112Abstract: The present disclosure relates to novel lipocalin muteins which bind to PCSK9. The disclosure also provides corresponding nucleic acid molecules encoding lipocalin muteins and methods for producing lipocalin muteins as well as their encoding nucleic acid molecules.Type: ApplicationFiled: February 28, 2017Publication date: June 22, 2017Applicant: Daiichi Sankyo Co., Ltd.Inventors: Gabriele MATSCHINER, Christine ROTHE, Andreas HOHLBAUM, Andrea ALLERSDORFER, Rachida Siham Bel AIBA, Marlon HINNER, Alexander WIEDENMANN, Bradley LUNDE, Shinji YAMAGUCHI, Takahide ABURATANI, Ryuji HASHIMOTO, Tohru TAKAHASHI, Chikako NAGASAKI, Futoshi NARA, Tomohiro NISHIZAWA
-
Publication number: 20170166615Abstract: The present disclosure provides hNGAL muteins that bind CGRP and can be used in various application including pharmaceutical applications, for example, migraine. The present disclosure also concerns methods of making one or more muteins described herein as well as compositions and combinations comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules.Type: ApplicationFiled: December 7, 2016Publication date: June 15, 2017Applicant: Daiichi Sankyo Co., Ltd.Inventors: GABRIELE MATSCHINER, Christine ROTHE, Alexander WIEDENMANN, Rachida Siham BEL AIBA, Marlon HINNER, Andrea ALLERSDORFER, Bradley LUNDE, Kazufumi KUBOTA, Mitsuhiro MAKINO, Sakiko TAKAHASHI, Ryuji HASHIMOTO, Tohru TAKAHASHI, Mamoru OTOYO
-
Publication number: 20170114109Abstract: The present invention relates to a novel library for the generation of muteins and to novel muteins derived from human lipocalin 2 (Lcn2, hNGAL) and related proteins that bind a given target with detectable affinity. The invention also relates to corresponding nucleic acid molecules encoding such a mutein and to a method for their generation. The invention further relates to a method for producing such a mutein. For example, such muteins may serve to bind and deplete pathological forms of natural biomolecules such as the amyloid beta peptide in Alzheimer's disease or may target the fibronectin extra-domain B, which is associated with tumor neovasculature.Type: ApplicationFiled: December 15, 2016Publication date: April 27, 2017Applicant: Pieris Pharmaceuticals GmbHInventors: ARNE SKERRA, Michaela GEBAUER, Dominik HINZ, Sabine RAUTH, Gabriele MATSCHINER, Martin HUELSMEYER
-
Patent number: 9598476Abstract: The present disclosure relates to novel lipocalin muteins which bind to PCSK9. The disclosure also provides corresponding nucleic acid molecules encoding lipocalin muteins and methods for producing lipocalin muteins as well as their encoding nucleic acid molecules.Type: GrantFiled: August 28, 2015Date of Patent: March 21, 2017Assignee: Daiichi Sankyo Co., Ltd.Inventors: Gabriele Matschiner, Christine Rothe, Andreas Hohlbaum, Andrea Allersdorfer, Rachida Siham Bel Aiba, Marlon Hinner, Alexander Wiedenmann, Bradley Lunde, Shinji Yamaguchi, Takahide Aburatani, Ryuji Hashimoto, Tohru Takahashi, Chikako Nagasaki, Futoshi Nara, Tomohiro Nishizawa
-
Patent number: 9549968Abstract: The present invention relates to a novel library for the generation of muteins and to novel muteins derived from human lipocalin 2 (Lcn2, hNGAL) and related proteins that bind a given target with detectable affinity. The invention also relates to corresponding nucleic acid molecules encoding such a mutein and to a method for their generation. The invention further relates to a method for producing such a mutein. For example, such muteins may serve to bind and deplete pathological forms of natural biomolecules such as the amyloid beta peptide in Alzheimer's disease or may target the fibronectin extra-domain B, which is associated with tumor neovasculature.Type: GrantFiled: December 7, 2010Date of Patent: January 24, 2017Assignee: Pieris Pharmaceuticals GmbHInventors: Arne Skerra, Michaela Gebauer, Dominik Hinz, Sabine Rauth, Gabriele Matschiner, Martin Huelsmeyer
-
Publication number: 20160362460Abstract: The disclosure provides a multi-specific polypeptide with a first moiety specific for a tumor-associated antigen on tumor cell surface and a second moiety specific for an immune checkpoint protein, which multi-specific polypeptide can be useful for biasing a T-cell-mediated response to a tumor micro-environment. For example, the polypeptide may contain: a) a first binding domain, for example, a full-length antibody or an antigen-binding domain of an antibody, specifically recognizing a tumor-associated antigen on tumor cell surface, and b) a second binding domain, such as a lipocalin mutein, capable of stimulating T-cell proliferation e.g., by inhibiting a protein receptor that down-regulates the immune system. The first binding domain may be genetically linked (i.e., peptide bond at its N- or C-terminus) to the second binding domain. The multispecific polypeptide also may contain a third or yet additional specific binding moieties, any of which can specifically bind a distinct immune checkpoint protein.Type: ApplicationFiled: January 12, 2015Publication date: December 15, 2016Applicant: Pieris Pharmaceuticals GmbHInventors: SHANE OLWILL, Alexander WIEDENMANN, Andrea ALLERSDORFER, Rachida BEL AIBA, Gabriele MATSCHINER, Bradley LUNDE
-
Publication number: 20160200780Abstract: The present invention relates to novel muteins derived from human tear lipocalin having affinity to human c-Met receptor tyrosin kinase (c-Met). The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.Type: ApplicationFiled: December 14, 2015Publication date: July 14, 2016Applicant: PIERIS AGInventors: GABRIELE MATSCHINER, ANDREAS HOHLBAUM, MARTIN HUELSMEYER, STEFAN TRENTMANN
-
Patent number: 9260492Abstract: Described are specific-binding therapeutic and/or diagnostic proteins directed against Glypican-3 (GPC3), which proteins include muteins of a lipocalin protein, such as lipocalin 2 (Lcn2 or NGAL). The invention also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. Accordingly, the invention also is directed to pharmaceutical and/or diagnostic compositions comprising such lipocalin proteins, including uses of these proteins.Type: GrantFiled: November 15, 2011Date of Patent: February 16, 2016Assignee: Pieris AGInventors: Gabriele Matschiner, Andreas Hohlbaum, Kristian Jensen
-
Publication number: 20160024161Abstract: The present disclosure relates to novel lipocalin muteins which bind to PCSK9. The disclosure also provides corresponding nucleic acid molecules encoding lipocalin muteins and methods for producing lipocalin muteins as well as their encoding nucleic acid molecules.Type: ApplicationFiled: August 28, 2015Publication date: January 28, 2016Applicant: Daiichi Sankyo Co., Ltd.Inventors: Gabriele MATSCHINER, Christine Rothe, Andreas Hohlbaum, Andrea Allersdorfer, Rachida Siham Bel Aiba, Marlon Hinner, Alexander Wiedenmann, Bradley Lunde, Shinji Yamaguchi, Takahide Aburatani, Ryuji Hashimoto, Tohru Takahashi, Chikako Nagasaki, Futoshi Nara, Tomohiro Nishizawa
-
Patent number: 9221885Abstract: The present invention relates to novel, specific-binding therapeutic and/or diagnostic proteins directed against Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) also known as CD152, which proteins preferably are muteins of a lipocalin protein, more preferably of lipocalin 2 (Lcn2 or NGAL). The invention also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. Accordingly, the invention also is directed to pharmaceutical and/or diagnostic compositions comprising such lipocalin proteins, including uses of these proteins.Type: GrantFiled: December 2, 2011Date of Patent: December 29, 2015Assignee: Pieris AGInventors: Gabriele Matschiner, Andreas Hohlbaum, Arne Skerra
-
Patent number: 9212208Abstract: The present invention relates to novel muteins derived from human tear lipocalin having affinity to human c-Met receptor tyrosin kinase (c-Met). The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.Type: GrantFiled: January 29, 2009Date of Patent: December 15, 2015Assignee: Pieris AGInventors: Gabriele Matschiner, Andreas Hohlbaum, Martin Huelsmeyer, Stefan Trentmann
-
Publication number: 20150344538Abstract: The present invention relates to novel, specific-binding therapeutic and/or diagnostic polypeptides directed against the target of Swiss Prot Q16552 and novel, specific-binding therapeutic and/or diagnostic polypeptides directed against the target of Swiss Prot Q9NPF7. In addition, the present invention relates to novel, specific-binding therapeutic and/or diagnostic polypeptides directed against one or both of Swiss Prot Q16552 and Swiss Prot Q9NPF7. The invention also relates to nucleic acid molecules encoding such polypeptides and to methods for generation of such polypeptides and nucleic acid molecules. In addition, the invention is directed to compositions comprising the polypeptides, and therapeutic and/or diagnostic uses of these polypeptides.Type: ApplicationFiled: November 20, 2013Publication date: December 3, 2015Applicant: PIERIS AGInventors: Marlon HINNER, Laurent AUDOLY, Martin HUELSMEYER, Kristian JENSEN, Gabriele MATSCHINER, Shane OLWILL, Alexander WIEDENMANN, Andrea ALLERSDORFER
-
Publication number: 20150291675Abstract: The present invention relates to novel, specific-binding therapeutic and/or diagnostic proteins directed against Hepcidin, which proteins preferably are muteins of lipocalin protein. The invention also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. Accordingly, the invention also is directed to pharmaceutical and/or diagnostic compositions comprising such a lipocalin proteins, including uses of these proteins.Type: ApplicationFiled: May 6, 2015Publication date: October 15, 2015Applicant: PIERIS AGInventors: STEFAN TRENTMANN, GABRIELE MATSCHINER, ARNE SKERRA, ANDREAS HOHLBAUM, MARTIN HUELSMEYER, HENDRIK GILLE, HANS-JUERGEN CHRISTIAN, KRISTIAN JENSEN, RACHIDA SIHAM BEL AIBA
-
Publication number: 20150283207Abstract: The present invention relates to novel muteins derived from human tear lipocalin, which bind to IL 4 receptor alpha. The sequences of the muteins comprise particular combinations of amino acids. In particular a mutated amino acid residue is present at any one or more of the sequence positions 27, 28, 30, 31, 33, 53, 57, 61, 64, 66, 80, 83, 104-106 and 108 of the linear polypeptide sequence of the mature human tear lipocalin. A mutated amino acid residue is also present at any 2 or more of the sequence positions 26, 32, 34, 55, 56, 58 and 63 of the linear polypeptide sequence of the mature human tear lipocalin. The invention also provides a corresponding nucleic acid molecule encoding such a mutein and a method for producing such a mutein and its encoding nucleic acid molecule.Type: ApplicationFiled: March 23, 2015Publication date: October 8, 2015Applicant: PIERIS AGInventors: Andreas HOHLBAUM, Alexandra Baehre, Gabriele Matschiner, Stefan Trentmann, Klaus Kirchfield, Hans-Juergen Christian
-
Patent number: 9150629Abstract: The present disclosure relates to novel lipocalin muteins which bind to PCSK9. The disclosure also provides corresponding nucleic acid molecules encoding lipocalin muteins and methods for producing lipocalin muteins as well as their encoding nucleic acid molecules.Type: GrantFiled: March 13, 2014Date of Patent: October 6, 2015Assignee: DAIICHI SANKYO CO., LTD.Inventors: Gabriele Matschiner, Christine Rothe, Andreas Hohlbaum, Andrea Allersdorfer, Rachida Siham Bel Aiba, Marlon Hinner, Alexander Wiedenmann, Bradley Lunde, Shinji Yamaguchi, Takahide Aburatani, Ryuji Hashimoto, Tohru Takahashi, Chikako Nagasaki, Futoshi Nara, Tomohiro Nishizawa
-
Patent number: 9051382Abstract: The present invention relates to novel, specific-binding therapeutic and/or diagnostic proteins directed against Hepcidin, which proteins preferably are muteins of a lipocalin protein. The invention also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. Accordingly, the invention also is directed to pharmaceutical and/or diagnostic compositions comprising such a lipocalin proteins, including uses of these proteins.Type: GrantFiled: August 16, 2011Date of Patent: June 9, 2015Assignee: PIERIS AGInventors: Stefan Trentmann, Gabriele Matschiner, Arne Skerra, Andreas Hohlbaum, Martin Huelsmeyer, Hendrik Gille, Hans-Juergen Christian, Kristian Jensen, Rachida Siham Bel Aiba
-
Patent number: 8986951Abstract: The present invention relates to novel muteins derived from human tear lipocalin, which bind to IL 4 receptor alpha. The sequences of the muteins comprise particular combinations of amino acids. In particular a mutated amino acid residue is present at any one or more of the sequence positions 27, 28, 30, 31, 33, 53, 57, 61, 64, 66, 80, 83, 104-106 and 108 of the linear polypeptide sequence of the mature human tear lipocalin. A mutated amino acid residue is also present at any 2 or more of the sequence positions 26, 32, 34, 55, 56, 58 and 63 of the linear polypeptide sequence of the mature human tear lipocalin. The invention also provides a corresponding nucleic acid molecule encoding such a mutein and a method for producing such a mutein and its encoding nucleic acid molecule.Type: GrantFiled: June 8, 2011Date of Patent: March 24, 2015Assignee: Pieris AGInventors: Andreas Hohlbaum, Alexandra Baehre, Gabriele Matschiner, Stefan Trentmann, Klaus Kirchfeld, Hans-Juergen Christian